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A 52-year-old Caucasian woman suffering from pain in the anterior maxillary 
region, presented to the clinic. Examination revealed a draining sinus tract in the 
buccal vestibule of the maxilla in the left anterior segment and expansion in the 
middle of palate. On conventional radiographic examination the lesion was 
initially assumed to be a periapical problem related to the incisors but 
subsequently it was diagnosed to be a bisphosphonate osteonecrosis. 
Conclusion: Acquiring a comprehensive medical history from the patients, 
conducting the clinical vitality tests and most importantly being familiar with 
the non-odontogenic lesions that can be side effects of specific medications are 
important requirements for reaching a correct diagnosis.  
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Introduction 
any malignancies have tendency to involve the 
surrounding/distant bone structures as in 75% of the 
patients with breast cancer, bone metastases occur [1]. The 
metastatic lesions are sometimes accompanied by skeletal 
morbidity and severe pain. Prevention of these complications 
subsequent to cancer diagnosis is very important [2].  
Medicines from bisphosphonate group are used for treatment 
of metabolic bone diseases (e.g. Paget disease), osteoporosis, 
multiple myeloma, etc. [3, 4] and are considered as the standard 
modality in prevention of skeletal complications in patients with 
bone metastases [5]. The mechanism of action is through 
inhibition of osteoclastic bone resorption and prevention of 
tumor cells proliferation and angiogenesis [3]. 
Intravenous zoledronic acid (zoledronate) was the first 
introduced bisphosphonate for treatment of bone metastases after 
the breast carcinoma [2] and was approved for prevention of 
skeletal lesions in patients with multiple myeloma or bone 
metastases of any solid tumor [5, 6]. However, during the past 
years, bisphosphonates, especially intravenous preparations, are 
held responsible for osteonecrosis of the jaws (ONJ) [3]. ONJ was 
first described in 2003 [7], as the transmucosal exposure of jaw 
bone for at least eight weeks, in a patient with history of 
bisphosphonate consumption without any history of 
radiotherapy in the head and neck region [8]. In most of the cases 
bone exposure is clinically obvious [9]. 
Based on retrospective studies, the rate of bisphosphonate-
related ONJ is up to 19% in patients with bone metastasis [9] and 
zoledronate is more dominantly responsible for ONJ [2]. The 
mandible is more commonly affected than the maxilla with a 2:1 
ratio [3, 9]. The present case describes the challenges brought to 
the clinicians during examination and diagnosis of a bone lesion 
surrounding the left maxillary canine that was diagnosed as 
bisphosphonate-related ONJ after many sessions of orthograde 
and retrograde endodontic treatments. 
Case Report 
A 52-year old female with her chief complaint being pain in 
anterior left maxillary region, was referred to a private 
maxillofacial imaging center, by a general practitioner.  
According to the dentist, she had a history of breast cancer, 
mastectomy and chemotherapy. During clinical examination of 
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Figure 1. A and B) The presence of sinus tract and swelling in the left lateral incisor and canine in the buccal vestibule and palate; C) Periapical 
lucency surrounding the left lateral incisor and canine; D) Persistent lesions after orthograde treatment led to periapical surgery; E) Extraction of 
the canine; F-I) Reoccurrence of the sinus tract and palatal swelling; J and K) Appearance of similar lesions on the right maxillary side 
 
the buccal vestibule in the left lateral and canine region, a 
draining sinus tract was detected. Also in the middle of palate a 
firm pediculate expansion was seen (Figures 1A and B). No other 
clinical sign was present. The canine, like other anterior teeth, 
was covered with full PFM restoration. 
For more evaluation periapical radiography was ordered. 
The images revealed periapical radiolucency and widening of the 
periodontal ligament (PDL) surrounding the left lateral incisor 
and canine (Figure 1C). The teeth were not endodontically 
treated and considering the clinical and radiographic 
manifestations, two-session root canal therapy with two-week 
calcium hydroxide intracanal medication was performed. 
However, signs and symptoms did not resolve and periapical 
surgery was indicated (Figure 1D).  
After surgery, 500 mg amoxicillin and 250 mg metronidazole 
was prescribed every 8 h for seven days. During the couple of 
weeks after surgery the patient reported no complications. 
However, she returned shortly after the end of antibiotic therapy, 
due to recurrence of pain and pus drainage. Finally the dentist 
decided to extract the canine (Figure 1E). Unfortunately, after one 
week not only the sinus tract re-occurred on the left side of maxilla 
(Figures 1F to I) but also similar lesions appeared on the right 
maxillary posterior segment (Figures 1J and K). 
The dentist referred the patient to the maxillofacial radiologist 
for more evaluation. After more assessment of the radiographies 
the generalized PDL widening in anterior maxilla and sclerosis of 
trabecular bone was detected (Figure 2A). Also; cone-beam 
computed tomography (CBCT) imaging was indicated (Figure 
2B) which revealed the perforation of the palatal cortex in 
addition to the sequester formation (Figures 2B and C). 
Considering the clinical and para-clinical findings and patient’s 
medical history, she was questioned about consumption of 
additional non-declared medicine. She approved consumption of 
4 mg/5 mL intra-venous zometa for the past four years to prevent 
bone metastasis.  
As a result the primary diagnosis was bisphosphonate-
related ONJ and the patient was referred to an oral-maxillofacial 
surgeon in order to take a biopsy. Histological assessment 
showed areas of necrotic bone with signs of infection and also 
regions with increased bone turnover which was compatible 
with ONJ and confirmed the final diagnosis. The patient was 
referred for treatment. 
Discussion 
The present report represented the challenging diagnosis of a 
bisphosphonate-related ONJ that had the clinical profile of a 
common endodontic lesion with draining sinus tract; after non-
surgical and surgical endodontic intervention and persistence of 
the lesion the general practitioner suspected a non-odontogenic 
lesion. A revision through patient’s medical history (breast cancer 
and bisphosphonate therapy for prevention of bone metastasis) 
confirmed the final diagnosis. 
The question is if there was a space for prompt diagnosis 
during the first visits by the dentist. The answer may be positive. 
The dentist failed to elicit the list of medicines consumed by the 
patient considering a history of malignancy, mastectomy and 
chemotherapy. But if the dentist was aware of patient’s injection 
of zometa, could he/she still consider the clinical relevance of it? 
Bisphosphonates are analogous to synthetic pyrophosphate 
that concentrate in areas of bone and thus are powerful inhibitors 
of osteoclastic activity [3, 10] and have high affinity for 
hydroxyapatite crystals [3]. They have low intestinal absorption 
and are excreted through the kidneys without metabolic alteration 
[11]; as a result they are absorbed into the skeleton without 
degradation and have the incredibly long half-life of up to 12 years 
[3, 5]. Bisphosphonates cause resistance to osteoclastic activity 
[11] and are able to reduce the rate of pathological fractures, bone 
pain, the need for radiotherapy and surgery in patients with bone 
metastases [7, 9].  
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Figure 2. A) Generalized PDL widening in anterior maxilla and sclerosis of trabecular bone; B and C) Perforation of the palatal cortex in and 
sequester formation 
 
As the newer member of this family, amino-bisphosphonates 
(alendronate, risidronate, pamidronate, zoledronic acid and 
ibandronate) have several anti-tumor effects, such as induction of 
cell apoptosis, inhibition of cell adhesion to the extracellular 
matrix and inhibition of tumor invasion [12, 13]. 
The use of bisphosphonates in patients with multiple 
myeloma, primary and metastatic bone malignancies (breast, 
prostate, lung and renal cell carcinomas) [13], has reduced the 
skeletal complications, such as pathologic fractures, spinal cord 
compression, hypercalcemia secondary to malignancies and the 
need for bone radiotherapy or surgery [3, 14]. Our patient had a 
history of breast cancer and, although late, mentioned the 
consumption of intra-venous zoledronic acid for the past four 
years. In treatments exceeding 36 months with bisphosphonates 
the increasing risk of osteonecrosis increases which is more 
noticeable with the use of zoledronic acid and pamidronate [3]. 
Bisphosphonates have many oral complications: oral mucosal 
lesions arising from direct contact injury in cases of oral 
consumption [3] and induction of avascular osteonecrosis in 
maxilla and mandible [15]. In the present case, maxilla was 
involved unilaterally which became bilateral after some time. The 
only clinical manifestation was the presence of a sinus tract and a 
periradicular lucency around the crown-restored canine. ONJ has 
been reported as the exposure of mandibular (65%) or maxillary 
(26%) bone or both (9%) which is painless in one third of the cases 
[16] and has a tendency to occur on female patients and in 
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posterior mandible [3]. In 40% of the cases it occurs 
spontaneously [7, 15] and bilateral involvement was slightly more 
common in the maxilla [3]. Clinically, intraoral lesions appear as 
areas of exposed yellowish hard bone with smooth or ragged 
borders and extra/intra oral sinus tracts may be present [9]. In our 
patient only sinus tract was present. In radiographies widening of 
the periodontal ligament is obvious which can be confusing and 
lead to misdiagnosis of periodontal issues [16]. We shall say if the 
dentist had radiographically evaluated the anterior segment, 
he/she would have detected the generalized PDL widening in our 
patient. Although this could be also attributed to necrotized 
crowned anterior teeth. The presence of full restorations 
challenged conducting pulp vitality tests.  
Poorly defined radiolucencies with moth-eaten borders, 
with or without radiopaque sequestra can be seen in advanced 
cases [3, 9], which was not detected in routine radiographies of 
the present case. Even surface colonization of the exposed bone 
by organisms of dental plaque such as Actinomyces can be 
detected by culturing, which is hard to distinguish from a true 
suppurative infection such as osteomyelitis [3]. Among the 
routine signs of ONJ including pain, swelling, fever, purulent 
secretion and oroanthral sinus tracts [15], our patient 
presented only the last two signs. 
There are many medical conditions that can alter the 
procedure of routine dental treatments. The fact that if the 
patient’s problem was diagnosed earlier periapical surgery would 
not be chosen, emphasizes on the necessity of meticulous history 
taking before diagnosis and treatment. 
Conclusion 
Although diagnosis of this case was particularly challenging, it 
was finally achieved. Taking a comprehensive history, especially 
from medically compromised patients and a complete list of 
patients’ medicines in addition to pulp vitality tests can help the 
clinician avoid “tunnel vision” during evaluation of the patient. 
This will provide the keys to successful diagnosis and treatment. 
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